Neuraxis, INC 10-Q quarterly reports

NeurAxis, Inc. announced a significant increase in net sales and gross profit for the second quarter of 2026, driven by expanded insurance coverage for its IB-Stim device.

Neuraxis, Inc. announced its first quarter 2026 financial results, showcasing a significant 79.5% year-over-year increase in net sales driven by expanded insurance coverage for its IB-Stim device.

NeurAxis, Inc. reported increased net sales for Q3 and the nine months ended September 30, 2025, but continues to face significant operating losses and a going concern warning from its auditors.

Neuraxis, Inc. reported increased net sales and a reduced net loss for Q2 2025, bolstered by a significant capital raise, despite ongoing operational losses and a 'going concern' warning.

NeurAxis, Inc. reports a revenue increase of 38.5% year-over-year for Q1 2025, but also a widening net loss due to increased expenses.

Neuraxis Inc. saw a revenue increase in Q3 2024, but continues to operate at a loss while addressing internal control weaknesses.

NeurAxis Inc. reported a decrease in revenue for the second quarter of 2024, alongside increased operating losses, as the company focuses on securing insurance coverage and managing its transition to a public entity.

Neuraxis Inc. reported a net loss of $2.12 million for the first quarter of 2024, with a decrease in sales and an increase in operating expenses, while focusing on insurance coverage and capital funding.